Kevin Harrington
Professor Kevin Harrington is a prominent oncologist and researcher who led a significant clinical trial in the UK exploring the effectiveness of the immunotherapy drug pembrolizumab for treating advanced head and neck cancers. His work has been instrumental in demonstrating how this treatment could potentially double survival rates and revolutionize care for patients with these challenging cancers.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Iran | 1 | 5.00 | 0.08% | +0% | 83,992,949 | 63,824 | $610,000 | 464$ |
| Totals | 1 | 83,992,949 | 63,824 | $610,000 | 464$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Iran:
Kevin Harrington is the Senior Director of Strategic Planning at the National Security Council and participated in the process led by Anton.
5
United Kingdom:
Kevin Harrington is one of the two senior White House officials at the Stockholm conference.
6
United Kingdom:
Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research, London, led a UK team involved in the trial.
8
United Kingdom:
Prof Kevin Harrington, who led the trial in the UK, explains the benefits of the immunotherapy drug pembrolizumab.
8